1.725

2.54% -0.045

After Hours: 1.68 -0.045 -2.61%

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $1.725, with a volume of 672.58K. It is down -2.54% in the last 24 hours and down -28.42% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$1.77

Open:

$1.79

24h Volume:

672.58K

Relative Volume:

0.74

Market Cap:

$186.49M

Revenue:

$42.51M

Net Income/Loss:

$-116.49M

P/E Ratio:

-1.5402

EPS:

-1.12

Net Cash Flow:

$-120.82M

1W Performance:

-12.44%

1M Performance:

-28.42%

6M Performance:

-79.49%

1Y Performance:

-78.83%

1-Day Range:

$1.705

$1.855

1-Week Range:

$1.705

$2.04

52-Week Range:

$1.705

$12.02

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

155

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	1.725	186.49M	42.51M	-116.49M	-120.82M	-1.12
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

Mar 13, 2025

Tango Therapeutics executive sells shares worth $43,865 - MSN

Mar 13, 2025

Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World

Mar 13, 2025

Mar 10, 2025

Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 07, 2025

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN

Mar 07, 2025

Feb 28, 2025

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat

Feb 28, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St

Feb 28, 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK

Feb 28, 2025

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Feb 28, 2025

Feb 27, 2025

Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Feb 27, 2025